An interventional study of Auricular Vagus Nerve Stimulation (VIVO®) and Standard of Care (Investigator Choice) in Chronic Low Back Pain, sponsored by Algemeen Ziekenhuis Maria Middelares. Recruiting at 1 site in Belgium. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Algemeen Ziekenhuis Maria Middelares · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to evaluate whether auricular vagus nerve stimulation using the VIVO® device can improve function and reduce pain in adults with high-impact chronic low back pain when added to standard medical care. It will also assess the safety and usability of this therapy.
The study includes adult patients aged 30 to 55 years who have had moderate to severe chronic low back pain for more than 6 months and who did not experience sufficient relief with standard pain treatments.
The main questions this study aims to answer are:
Researchers will compare standard care plus VIVO® to standard care alone to see if the device improves outcomes.
Standard care may include medication, physiotherapy, or other usual treatments.
The main outcome is the change in disability (measured using the Oswestry Disability Index) after 6 weeks of treatment.
Participants will:
Participants in the intervention group will:
Receive a VIVO® wearable device applied to the ear, which delivers electrical stimulation to the vagus nerve; Use the device continuously over 6 weeks, with weekly replacement and adjustment of stimulation settings; Be able to adjust the stimulation intensity themselves using a handheld device.
After the treatment period, all participants will be followed for 12 months, with additional visits or contacts to assess long-term effects, safety, and sustainability of the treatment.
This is a prospective, interventional, open-label, randomized controlled, single-center clinical trial evaluating the effectiveness, safety, and usability of auricular vagus nerve stimulation using the VIVO® device in addition to standard of care in adults with high-impact chronic low back pain.
Chronic low back pain remains a major clinical challenge, as many people experience insufficient relief with currently available treatments. Standard approaches such as pharmacological therapy, physiotherapy, and multidisciplinary care often provide only partial improvement. There is therefore a need for additional non-pharmacological treatment options that may improve function and reduce pain.
Auricular vagus nerve stimulation (aVNS) is a minimally invasive neuromodulation technique that delivers electrical stimulation to the auricular branch of the vagus nerve. The VIVO® device is a CE-marked, wearable medical device that applies electrical impulses via small needle electrodes placed in the ear. This stimulation is thought to modulate pain processing through effects on the autonomic nervous system and central pain pathways, potentially supporting pain relief and improved function.
In this study, participants are randomized in a 1:1 ratio to receive either standard of care alone or standard of care combined with VIVO® therapy. The intervention period lasts 6 weeks. Participants in the intervention group receive a VIVO® device that is applied to the ear and replaced weekly, alternating between ears. The stimulation intensity is adjusted based on individual tolerance to achieve a comfortable sensation. Participants are also trained to adjust the stimulation amplitude using a handheld device.
Throughout the treatment period, participants attend regular study visits during which clinical assessments, patient-reported outcomes, and safety data are collected. During follow-up, participants are monitored for up to 12 months to evaluate the durability of treatment effects and to assess longer-term safety and usability.
The study is designed to evaluate whether the addition of aVNS therapy improves functional outcomes compared to standard of care alone. In addition, the study will explore the broader impact of treatment on pain experience, daily functioning, and patient-reported wellbeing. Usability of the device and participant satisfaction are also assessed to better understand how this therapy can be applied in clinical practice.
Safety monitoring will be conducted throughout the study, including the collection and evaluation of adverse events and device-related effects. The expected safety profile of aVNS is favorable, with mainly mild and local side effects such as skin irritation or discomfort at the application site.
The results of this study will provide further evidence on the role of auricular vagus nerve stimulation as a non-pharmacological treatment option for chronic low back pain and may help inform future patient selection and clinical use of this therapy.
2,922 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.
This study's planned enrollment of 44 is below the median of 60 across 2,364 interventional studies indexed under Low Back Pain.
Browse Low Back Pain studies →Algemeen Ziekenhuis Maria Middelares is the lead sponsor of 37 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive standard medical care for chronic low back pain. No VIVO® device is used in this group.
Other: Standard of Care (Investigator Choice)
Participants receive standard of care in combination with auricular vagus nerve stimulation using the VIVO® device for 6 weeks.
Device: Auricular Vagus Nerve Stimulation (VIVO®)
Auricular vagus nerve stimulation (aVNS) is delivered using the VIVO® device, a CE-marked wearable medical device that applies electrical stimulation to the auricular branch of the vagus nerve via electrodes placed on the ear. The device is worn continuously during a 6-week treatment period and replaced weekly, alternating between ears. Stimulation intensity is adjusted based on individual tolerance using a handheld controller. This intervention is administered in addition to standard of care.
Participants receive standard medical care for chronic low back pain as determined by the treating physician. This may include pharmacological treatment, physiotherapy, behavioral therapy, and other non-invasive or invasive therapies as clinically indicated.
Change in Oswestry Disability Index (ODI) from Baseline to 6 Weeks
The primary outcome is the change in functional disability, measured using the Oswestry Disability Index (ODI), from baseline to the end of the treatment at 6 weeks. The ODI is a validated questionnaire assessing limitations in daily activities related to low back pain, with total scores ranging from 0 to 100, where higher scores indicate greater disability.
Time frame: Baseline to 6 weeks
Change in Oswestry Disability Index (ODI) over time
Change in functional disability measured using the Oswestry Disability Index (ODI) at predefined time points during the treatment period and follow-up visits. The ODI is a validated questionnaire assessing limitations in daily activities due to low back pain, with total scores ranging from 0 to 100, where higher scores indicate greater disability.
Time frame: Baseline to 12 months
Change in pain intensity using Numeric Rating Scale (NRS)
Change in pain intensity measured using the Numeric Rating Scale (NRS) at predefined time points during the treatment period and follow-up visits. The NRS is a patient-reported scale ranging from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity.
Time frame: Baseline to 12 months
Change in health-related quality of life using EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire
Change in health-related quality of life measured using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire from baseline to the end of the treatment and follow-up visits. The EQ-5D-5L consists of a descriptive system assessing five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with five levels of severity. Responses can be combined into a 5-digit health state profile, which can be converted into a single index value using a country-specific value set. Higher index scores indicate better health-related quality of life. The EQ visual analogue scale (EQ VAS) records the participant's self-rated health, where higher scores indicate better perceived health.
Time frame: Baseline to 12 months
Change in anxiety and depression using Hospital Anxiety and Depression Scale (HADS)
Change in anxiety and depression measured using the Hospital Anxiety and Depression Scale (HADS) from baseline to the end of the treatment and follow-up visits. The HADS is a validated questionnaire consisting of two subscales (anxiety and depression), each ranging from 0 to 21, with higher scores indicating greater symptom severity.
Time frame: Baseline to 12 months
Change in sleep quality using Pittsburgh Sleep Quality Index (PSQI)
Change in sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI) from baseline to the end of treatment and follow-up visits. The PSQI is a validated questionnaire assessing sleep quality, with total scores ranging from 0 to 21, where higher scores indicate worse sleep quality.
Time frame: Baseline to 12 months
Change in neuropathic pain characteristics using Douleur Neuropathique 4 questionnaire (DN4)
Change in neuropathic pain characteristics measured using the Douleur Neuropathique 4 questionnaire (DN4) from baseline to the end of treatment and follow-up visits. The DN4 is a validated questionnaire used to identify neuropathic pain, with total scores ranging from 0 to 10, where higher scores indicate a greater likelihood of neuropathic pain.
Time frame: Baseline to 12 months
Change in employment status over time
Change in employment status over time, assessed by recording participants' employment category (e.g., full-time employment, part-time employment, sick leave, invalidity, retirement) at predefined time points during the treatment period and follow-up.
Time frame: Baseline to 12 weeks
Change in pain medication use assessed by medication type and frequency
Change in pain medication use over time, assessed by recording the type and frequency of analgesic medications used by participants at predefined time points during the study period.
Time frame: Baseline to 12 months
Change in use of additional non-pharmacological therapies assessed by type and frequency
Change in the use of additional non-pharmacological therapies, including physiotherapy, assessed by recording the type and frequency of therapies received by participants at predefined time points during the study period.
Time frame: Baseline to 12 months
Patient satisfaction and device usability assessed using a VIVO Perception & Usability questionnaire
Evaluation of patient-reported satisfaction with treatment and usability of the VIVO® device and its accessories, assessed using the VIVO® Perception \& Usability Scale, a manufacturer-developed 14-item questionnaire rated on a 5-point ordinal scale. This questionnaire is designed to measure patient perception and practical experience with the device. The assessment is performed once at the end of the treatment period.
Time frame: At end of treatment period (week 6)
Physician and therapist satisfaction and device usability assessed using the VIVO® Perception & Usability Scale for Healthcare Professionals
Evaluation of physician and therapist satisfaction with treatment and usability of the VIVO® device and its accessories, assessed using the VIVO® Perception \& Usability Scale for Healthcare Professionals (HCPs), a manufacturer-developed 9-item questionnaire mostly rated on a 5-point ordinal scale. This questionnaire is designed to measure the perception and practical experience of healthcare professionals applying and treating patients with the VIVO® device. The assessment is performed once by the participating pain physician at the end of the treatment period for the last patient.
Time frame: At end of treatment period (week 6, last patient)
Incidence of adverse events
Assessment of adverse events occurring during the treatment and follow-up period, including type, frequency, and severity of events, as reported and recorded at predefined time points.
Time frame: Baseline to 12 months
Number of protocol deviations
Assessment of protocol deviations and non-conformities occurring during the study period, recorded throughout the treatment and follow-up period.
Time frame: Baseline to 12 months
Plan to share: No — Individual participant data (IPD) will not be shared. Data will be used for the purposes of this study and handled in accordance with applicable data protection regulations.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Sep 2027, 18 months after the start.
Of 1,231 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's planned 18 months is above that.
Counting every sponsor, half of 1,286 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Algemeen Ziekenhuis Maria Middelares